Elevance Health Reports Revenue Growth Amid Medicare Risk Challenges

Elevance Health reported a rise in revenue for the first quarter of 2026, reaching $50.2 billion, up from $48.9 billion the previous year. This growth was driven largely by $41.0 billion in premiums and $6.2 billion in product revenues. However, net income declined to $1.8 billion from $2.2 billion, with diluted earnings per share dropping to $8.00 from $9.61. The decrease in profit was significantly impacted by a $935 million provision related to Medicare Advantage risk-adjustment data submitted to the Centers for Medicare & Medicaid Services (CMS).

The company's new Operating Model Transformation Program, set for 2026-2027, also contributed $129 million in personnel-related costs this quarter. Despite financial pressures, Elevance's operations generated $4.3 billion in cash, a substantial increase from $1.0 billion the year before. Share buybacks totaled 3.7 million shares, equating to $1.1 billion, while dividends of $1.72 per share were distributed, maintaining shareholder equity at approximately $43.9 billion.

With potential regulatory challenges due to Medicare risk data adjustment provisions, Elevance faced $935 million in liabilities for resubmissions spanning 2015 to April 2023, following a CMS sanction notice. This financial liability may vary significantly, adding an element of unpredictability. As medical claims payable grew to $18.425 billion, the strengthened operating cash flow of $4.332 billion facilitated share repurchases and sustained dividends. Monitoring compliance with CMS's July 31, 2026 deadline will be critical for assessing future financial and regulatory outcomes.